Literature DB >> 4760722

The treatment of jaundice due to liver metastases by quadruple chemotherapy.

J Hughes, T A Stoker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4760722      PMCID: PMC2495694          DOI: 10.1136/pgmj.49.570.265

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  8 in total

1.  Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumors.

Authors:  J J Costanzi; C A Coltman
Journal:  Cancer       Date:  1969-03       Impact factor: 6.860

2.  Intrahepatic arterial infusion with 5-fluorouracil.

Authors:  F J Ansfield; G Ramirez; J L Skibba; G T Bryan; H L Davis; G W Wirtanen
Journal:  Cancer       Date:  1971-11       Impact factor: 6.860

3.  Factors influencing survival in patients with untreated hepatic metastases.

Authors:  B M Jaffe; W L Donegan; F Watson; J S Spratt
Journal:  Surg Gynecol Obstet       Date:  1968-07

4.  Survival of patients treated with systemic fluorouracil for hepatic metastases.

Authors:  A H Rapoport; R L Burleson
Journal:  Surg Gynecol Obstet       Date:  1970-05

5.  The influence of treatment on the survival of patients with hepatic metastases diagnosed by liver scanning.

Authors:  C M Mansfield; S Kramer; M E Southard
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1970-08

6.  Prognostic factors affecting adrenalectomy in patients with metastatic cancer of the breast.

Authors:  M L Schmidt; T Nemoto; T Dao; I D Bross
Journal:  Cancer       Date:  1971-05       Impact factor: 6.860

7.  Chemotherapy for liver cancer by protracted ambulatory infusion.

Authors:  R D Sullivan; W Z Zurek
Journal:  JAMA       Date:  1965-11-01       Impact factor: 56.272

8.  Seventy-five cases of solid tumours treated by a modified quadruple chemotherapy regime.

Authors:  I W Hanham; K A Newton; G Westbury
Journal:  Br J Cancer       Date:  1971-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.